Abbott Laboratories (ABT)

Currency in USD
99.63
+0.80(+0.81%)
Real-time Data·
ABT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
99.47102.13
52 wk Range
81.97137.49
Key Statistics
Prev. Close
98.83
Open
100.39
Day's Range
99.47-102.13
52 wk Range
81.97-137.49
Volume
12.3M
Average Vol. (3m)
13.36M
1-Year Change
-17.2973%
Book Value / Share
29.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
118.04
Upside
+18.48%
Members' Sentiments
Bearish
Bullish
ProTips
7 analysts have revised their earnings downwards for the upcoming period

Abbott Laboratories News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

20 Buy
7 Hold
0 Sell
Ratings:
27 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 118.04
(+18.48% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Bernstein SocGen Group
Buy117.00+17.19%110.00MaintainJul 17, 2026
Benchmark
Buy120.00+20.19%-MaintainJul 17, 2026
JPMorgan
Buy120.00+20.19%110.00MaintainJul 17, 2026
Piper Sandler
Buy118.00+18.19%115.00MaintainJul 17, 2026
Wells Fargo
Buy112.00+12.18%109.00MaintainJul 17, 2026

Abbott Laboratories SWOT Analysis


Analyst Perspectives
Learn about Abbott's average price target of $143, with estimates ranging from $133 to $159, reflecting varied views on its growth potential and market dynamics.
Innovation Leadership
Delve into Abbott's product breakthroughs, including the PFA System's early European approval and exceptional growth in diabetes care, driving market position.
Financial Fortitude
Explore Abbott's robust financial metrics, including $42.3B revenue, 56% gross margin, and 31% ROE, with 2025 guidance projecting 7.5-8.5% top-line growth.
Diversified Dominance
Abbott's multi-segment portfolio drives resilience, with strong organic growth and a 3.2 Financial Health Score, positioning it well in the healthcare sector.
Read full SWOT analysis

Abbott Laboratories Earnings Call Summary for Q2/2026

  • Abbott Q2 2026 EPS of $1.31 beat estimates by $0.03; revenue of $12.59B topped forecasts; shares surged 11.75% to $99.76 in premarket trading.
  • Company raised full-year adjusted EPS guidance to $5.45-$5.60; reaffirmed 6.5%-7.5% sales growth; Q3 EPS expected at $1.38-$1.46.
  • Comparable sales growth accelerated to 4.8% from slower prior quarters; gross margin expanded 100 basis points to 58.0% of sales.
  • Management cited strength in nutrition, electrophysiology, diagnostics, and cancer testing as key second-half growth drivers.
  • CEO Ford reaffirmed 7% long-term sales growth target; highlighted pipeline including Libre Duo, Volt 2.0, and Amulet 360 regulatory submissions.
Last Updated: 07/16/2026, 10:19 AM
Read Full Transcript

Earnings

Latest Release
Jul 16, 2026
EPS / Forecast
1.31 / 1.28
Revenue / Forecast
12.59B / 12.52B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 3.59%
Dividend Yield
2.82%
Industry Median 1.64%
Annualized Payout
2.52
Paid quarterly
5-Years Growth
+8.54%
Growth Streak

ABT Income Statement

Compare ABT to Peers and Sector

Metrics to compare
ABT
Peers
Sector
Relationship
P/E Ratio
32.3x26.2x−0.4x
PEG Ratio
−0.52−1.970.00
Price / Book
3.3x2.5x2.6x
Price / LTM Sales
3.7x2.6x3.1x
Upside (Analyst Target)
20.4%0.0%50.8%
Fair Value Upside
Unlock7.5%7.8%Unlock

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
758.77M43.56%67.74B
Other Institutional Investors
665.69M38.22%59.43B
Public Companies & Retail Investors
317.35M18.22%28.33B
Total
1.74B100.00%155.49B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.8.36%145,687,45813,005,519
Vanguard Capital Management, LLC6.48%112,949,93310,083,041

People Also Watch

283.95
TXN
-2.50%
145.38
WDAY
-0.03%
218.87
ADSK
+0.83%
238.70
ADBE
+1.44%
255.79
ABBV
+0.55%

FAQ

What Is the Abbott Labs (ABT) Stock Price Today?

The Abbott Labs stock price today is 99.63 USD.

What Stock Exchange Does Abbott Labs Trade On?

Abbott Labs is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Abbott Labs?

The stock symbol for Abbott Labs is "ABT."

Does Abbott Labs Pay Dividends? What’s The Current Dividend Yield?

The Abbott Labs dividend yield is 2.55%.

What Is the Abbott Labs Market Cap?

As of today, Abbott Labs market cap is 173.68B USD.

What Is Abbott Labs's Earnings Per Share (TTM)?

The Abbott Labs EPS (TTM) is 3.59.

When Is the Next Abbott Labs Earnings Date?

Abbott Labs will release its next earnings report on Oct 21, 2026.

From a Technical Analysis Perspective, Is ABT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Abbott Labs Stock Split?

Abbott Labs has split 7 times.

How Many Employees Does Abbott Labs Have?

Abbott Labs has 115000 employees.

What is the current trading status of Abbott Labs (ABT)?

As of Jul 17, 2026, Abbott Labs (ABT) is trading at a price of 99.63 USD, with a previous close of 98.83 USD. The stock has fluctuated within a day range of 99.47 USD to 102.13 USD, while its 52-week range spans from 81.97 USD to 137.49 USD.

What Is Abbott Labs (ABT) Price Target According to Analysts?

The average 12-month price target for Abbott Labs is 118.04 USD, with a high estimate of 135 USD and a low estimate of 92 USD. 20 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +18.48% Upside potential.

What Is the ABT Premarket Price?

ABT's last pre-market stock price is 99.52 USD. The pre-market share volume is 55,400.00, and the stock has decreased by 0.69, or 0.70%.

What Is the ABT After Hours Price?

ABT's last after hours stock price is 99.37 USD, the stock has decreased by 0.54, or 0.55%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.